Anhui Fengyuan Pharmaceutical Stock Forum

The company's low P/E ratio reflects its poor earnings performance and the market's limited growth expectations. Despite the market's projected 41% growth next year, investors don't see enough potential for earnings improvement to justify a higher P/E ratio.